Makers of Raptiva Remove Psoriasis Drug From Market Due to PML Risks
Links shared publicly online about this topic.
- 2,130total visits
Makers of Raptiva Remove Psoriasis Drug From Market Due to PML Risks
Genentech, makers of the psoriasis drug Raptiva (efalizumab) have announced a voluntary withdrawal of the drug from the US market after learning of a rare but serious risk to patients taking the drug.
View full resource at usrecallnews.com
Tags: Psoriasis, Drug, Raptiva, Genentech
Most Recently Shared on April 8, 2009 at 10:51 pm By:
New Recall Alert: Makers of Raptiva Remove Psoriasis Drug From Market Due to PML Risks http://tinyurl.com/cant5q
Advertisement
